Merck’s HS Data Validates the TL1A Pathway — and Helps Shattuck Labs

Merck’s tulisokibart met its Phase 2b HS goal and will move to Phase 3. H.C. Wainwright sees first anti-TL1A skin data as a class plus for Shattuck.